Advaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 600,000 Shares

Advaxis, Inc. (NASDAQ:ADXS) major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the business’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $4.30, for a total value of $2,580,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adage Capital Partners Gp, L.L also recently made the following trade(s):

  • On Tuesday, September 26th, Adage Capital Partners Gp, L.L sold 1,239,323 shares of Advaxis stock. The stock was sold at an average price of $4.42, for a total value of $5,477,807.66.

Advaxis, Inc. (NASDAQ:ADXS) traded down 2.471% during mid-day trading on Thursday, reaching $4.145. The company’s stock had a trading volume of 833,291 shares. Advaxis, Inc. has a one year low of $3.90 and a one year high of $11.14. The stock’s 50 day moving average is $5.37 and its 200 day moving average is $6.87. The firm’s market cap is $170.21 million.

Advaxis (NASDAQ:ADXS) last posted its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.43 million. On average, analysts anticipate that Advaxis, Inc. will post ($2.23) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/10/12/advaxis-inc-adxs-major-shareholder-adage-capital-partners-gp-l-l-sells-600000-shares.html.

ADXS has been the topic of several research analyst reports. BidaskClub upgraded Advaxis from a “hold” rating to a “buy” rating in a research note on Saturday, September 9th. ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Advaxis in a research note on Friday, September 15th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $19.00 target price on shares of Advaxis in a research note on Monday, September 25th.

Several hedge funds have recently modified their holdings of ADXS. Voya Investment Management LLC grew its holdings in shares of Advaxis by 20.3% during the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 2,975 shares during the last quarter. Cutler Capital Management LLC purchased a new position in shares of Advaxis during the second quarter worth about $130,000. Northern Capital Management LLC grew its holdings in shares of Advaxis by 14.6% during the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 2,650 shares during the last quarter. Stonebridge Capital Management Inc. purchased a new position in shares of Advaxis during the second quarter worth about $146,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Advaxis by 18.2% during the second quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 4,000 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

What are top analysts saying about Advaxis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Advaxis Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit